Stroke is one of the leading causes of mortality and morbidity worldwide, and few therapeutic treatments have shown beneficial effect clinically. One reason for this could be the lack of risk factors incorporated into the preclinical stroke research. We have previously demonstrated phenotypic receptor changes to be one of the injurious mechanisms occurring after stroke but mostly in healthy rats. The aim of this study was to investigate if hypertension has an effect on vasoconstrictive receptor responses to endothelin 1, sarafotoxin 6c and angiotensin II after stroke by inducing transient middle cerebral artery occlusion in spontaneously hypertensive rats and Wistar-Kyoto rats using the wire-myograph. We demonstrated an increased contractile response to endothelin 1 and extracellular potassium as well as an increased carbachol-induced dilator response in the middle cerebral arteries from hypertensive rats after stroke. This study demonstrates the importance of including risk factors in experimental stroke research.

Keywords:
Hypertension, Middle cerebral artery occlusion, Spontaneously hypertensive rats, Wistar-Kyoto rats, Wire-myograph, Vasoconstriction, Endothelin 1, Receptor
1.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al: Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation 2016; 133:e38–e60.
2.
O’Collins VE, Donnan GA, Macleod MR, Howells DW: Hypertension and experimental stroke therapies. J Cereb Blood Flow Metab 2013; 33: 1141–1147.
3.
Edvinsson LI, Povlsen GK: Vascular plasticity in cerebrovascular disorders. J Cereb Blood Flow Metab 2011; 31: 1554–1571.
4.
Ansar S, Vikman P, Nielsen M, Edvinsson L: Cerebrovascular ETB, 5-HT1B, and AT1 receptor upregulation correlates with reduction in regional CBF after subarachnoid hemorrhage. Am J Physiol Heart Circ Physiol 2007; 293:H3750–H3758.
5.
Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO 3rd, Panza JA: Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999; 33: 753–758.
6.
Iadecola C, Davisson RL: Hypertension and cerebrovascular dysfunction. Cell Metab 2008; 7: 476–484.
7.
Strandgaard S, Paulson OB: Regulation of cerebral blood flow in health and disease. J Cardiovasc Pharmacol 1992; 19:S89–S93.
8.
Paulson OB, Strandgaard S, Edvinsson L: Cerebral autoregulation. Cerebrovasc Brain Metab Rev 1990; 2: 161–192.
9.
Schiffrin EL: Endothelin and endothelin antagonists in hypertension. J Hypertens 1998; 16: 1891–1895.
10.
Arroja MM, Reid E, McCabe C: Therapeutic potential of the renin angiotensin system in ischaemic stroke. Exp Transl Stroke Med 2016; 8: 8.
11.
Faraco G, Moraga A, Moore J, Anrather J, Pickel VM, Iadecola C: Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation. Hypertension 2013; 62: 759–766.
12.
Mazzuca MQ, Khalil RA: Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem Pharmcaol 2012; 84: 147–162.
13.
Iadecola C, Gorelick PB: Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke 2004; 35: 348–350.
14.
Koizumi J, Yoshida Y, Nakazawa T, Ooneda G: Experimental studies of ischemic brain edema, I: a new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jnp J Stroke 1986; 8: 1–8.
15.
Encarnacion A, Horie N, Keren-Gill H, Bliss TM, Steinberg GK, Shamloo M: Long-term behavioral assessment of function in an experimental model for ischemic stroke. J Neurosci Methods 2011; 196: 247–257.
16.
Mulvany MJ, Halpern W: Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977; 41: 19–26.
17.
Kovács A, Móricz K, Albert M, Benedek A, Hársing LG, Szénási G: Decreased vasoconstrictor responses in remote cerebral arteries after focal brain ischemia and reperfusion in the rat, in vitro. Eur J Pharmacol 2010; 644: 154–159.
18.
Cao L, Xu CB, Zhang Y, Cao YX, Edvinsson L: Secondhand smoke exposure induces Raf/ERK/MAPK-mediated upregulation of cerebrovascular endothelin ETA receptors. BMC Neurosci 2011; 12: 109.
19.
Stenman E, Malmsjö M, Uddman E, Gidö G, Wieloch T, Edvinsson L: Cerebral ischemia upregulates vascular endothelin ETB receptors in rat. Stroke 2002; 33: 2311–2316.
20.
Maddahi A, Edvinsson L: Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway. BMC Neurosci 2008; 9: 85.
21.
Nour M, Scalzo F, Liebeskind DS: Ischemia-reperfusion injury in stroke. Interv Neurol 2013; 1: 185–199.
22.
Grell A-S, Mostajeran M, Frederiksen SD, Edvinsson L, Ansar S: Cerebrovascular gene expression in spontaneously hypertensive rats after transient middle cerebral artery occlusion. Neuroscience 2017; 367: 219–232.
23.
Barone FC, Globus MY, Price WJ, White RF, Storer BL, Feuerstein GZ, et al. Endothelin levels increase in rat focal and global ischemia. J Cereb Blood Flow Metab 1994; 14: 337–342.
24.
Bian LG, Zhang TX, Zhao WG, Shen JK, Yang GY: Increased endothelin-1 in the rabbit model of middle cerebral artery occlusion. Neurosci Lett 1994; 174: 47–50.
25.
Estrada V, Téllez MJ, Moya J, Fernández-Durango R, Egido J, Fernández Cruz AF: High plasma levels of endothelin-1 and atrial natriuretic peptide in patients with acute ischemic stroke. Am J Hypertens 1994; 7: 1085–1089.
26.
Brondani R, Rieder CRM, Valente D, Araújo LF, Clausell N: Levels of vascular cell adhesion molecule-1 and endothelin-1 in ischemic stroke: a longitudinal prospective study. Clin Biochem 2007; 40: 282–284.
27.
Ziv I, Fleminger G, Djaldetti R, Achiron A, Melamed E, Sokolovsky M: Increased plasma endothelin-1 in acute ischemic stroke. Stroke 1992; 23: 1014–1016.
28.
Stenman E, Edvinsson L: Cerebral ischemia enhances vascular angiotensin AT1 receptor-mediated contraction in rats. Stroke 2004; 35: 970–974.
29.
Hosomi N, Nishiyama A, Ban CR, Naya T, Takahashi T, Kohno M, et al: Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 2005; 134: 225–231.
30.
Yamakawa H, Phillips MI, Saavedra JM: Intracisternal administration of angiotensin II AT1 receptor antisense oligodeoxynucleotides protects against cerebral ischemia in spontaneously hypertensive rats. Regul Pept 2003; 111: 117–122.
31.
Nishimura Y, Ito T, Saavedra JM: Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemica in spontaneously hypertensive rats. Stroke 2000; 31: 2478–2486.
32.
Zhu YZ, Chimon GN, Zhu YC, Lu Q, Li B, Hu HZ, et al: Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats. Neuroreport 2000; 11: 1191–1194.
33.
Lu Q, Zhu YZ, Wong PT: Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport 2005; 16: 1963–1967.
34.
Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al: Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110: 843–848.
35.
McCarthy CA, Vinh A, Miller AA, Hallberg A, Alterman M, Callaway JK, et al: Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats. PLoS One 2014; 9:e95762.
36.
Szok D, Hansen-Schwartz J, Edvinsson L: In depth pharmacological characterization of endothelin B receptors in the rat middle -cerebral artery. Neurosci Lett 2001; 314: 69–72.
37.
Nilsson D, Wackenfors A, Gustafsson L, Edvinsson L, Paulsson P, Ingemansson R, et al: Increased ETA and ETB receptor contraction in the left internal mammary artery from patients with hypertension. J Hum Hypertens 2008; 22: 226–229.
38.
Cao L, Cao YX, Xu CB, Edvinsson L: Altered endothelin receptor expression and affinity in spontaneously hypertensive rat cerebral and coronary arteries. PLoS One 2013; 8:e73761.
39.
Ando H, Zhou J, Macova M, Imboden H, Saavedra JM: Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004; 35: 1726–1731.
40.
Mayhan WG: Impairment of endothelium-dependent dilatation of basilar artery during chronic hypertension. Am J Physiol 1990; 259:H1455–H1462.
41.
Vanhoutte PM, Shimokawa H, Tang EH, Feletou M: Endothelial dysfunction and vascular disease. Acta Physiol 2009; 196: 193–222.
42.
Zeiher AM, Drexler H, Saurbier B, Just H: Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92: 652–662.
43.
Pétrault O, Ouk T, Gautier S, Laprais M, Gelé P, Bastide M, et al: Pharmacological neutropenia prevents endothelial dysfunction but not smooth muscle functions impairment induced by middle cerebral artery occlusion. Br J Pharmacol 2005; 144: 1051–1058.
44.
Martinez-revelles S, Jime F, Caracuel L, Pe FJ, Planas AM, Vila E: Endothelial dysfunction in rat mesenteric resistance artery after transient middle cerebral artery occlusion. Pharmacology 2008; 325: 363–369.
45.
Adachi U, Tsutsumi Y, Iijima M, Mizuno S, Uchiyama S, Kitagawa K: Differences in endothelial function between ischemic stroke subtypes. J Stroke Cerebrovasc Dis 2015; 24: 2781–2786.
46.
Thompson LP, Bruner CA, Lamb FS, King CM, Webb RC: Calcium influx and vascular reactivity in systemic hypertension. Am J Cardiol 1987; 59: 29A–34A.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.